# US 2015/0246939 A1 · Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0246939 A1
- Document ID: US20150246939A1
- Status: Published application
- Kind: A1
- Application number: 14/439,855
- Filed: 2013-10-31
- Published: 2015-09-03
- Earliest claimed: 2012-10-31
- Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education
- Applicants: University of Pittsburgh - of the Commonwealth System of Higher Education
- Inventors: Neil Hukriede; Billy W. Day; Lee A. McDermott
- Web page: https://patentgrep.com/patent/US20150246939A1

## CPC

- C07F 9/4841: {Aromatic acids or derivatives (P-C aromatic linkage)}
- A61P 13/12: of the kidneys
- C07C 317/22: with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C 317/44: having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
- C07C 321/28: Sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
- C07C 323/16: the carbon skeleton containing six-membered aromatic rings
- C07C 323/20: with singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C 323/47: to oxygen atoms
- C07C 323/52: the carbon skeleton being acyclic and saturated
- C07C 323/60: with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
- C07C 323/62: having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
- C07D 213/75: Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
- C07F 9/3229: {Esters of aromatic acids (P-C aromatic linkage)}
- C07F 9/5325: {Aromatic phosphine oxides or thioxides (P-C aromatic linkage)}
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Compounds and compositions are provided that inhibit histone deacylase activity and which expand renal progenitor cell populations and improve kidney function in a damaged kidney. Methods of use of the compounds and compositions are provided.

## Claims

### Claim 1

A compound having the formula:
in which
R is S,
R1 is —NHR4 where R4 is OH, 2-aminophenyl, or 2-hydroxyphenyl,
R2 is phenyl, 2-chlorophenyl, or 3-chlorophenyl, and
R3 is —CH2—CH2—CH2— or —CH2—CH2—CH2—CH2—CH2—,
wherein when R2 is phenyl, R4 is 2-hydroxyphenyl and when R2 is 3-chlorophenyl, and R3 is
—CH2—CH2—CH2—CH2—CH2—, R4 is OH or 2-aminophenyl,
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound of claim 1, in which R2 is phenyl and R4 is 2-hydroxyphenyl.

### Claim 3 (depends on 1)

The compound of claim 1, in which R3 is —CH2—CH2—CH2—.

### Claim 4 (depends on 1)

The compound of claim 1, having the formula:
or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 1)

The compound of claim 1, having the formula:
or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 1)

The compound of claim 1, in which R2 is 2-chlorophenyl.

### Claim 7 (depends on 1)

The compound of claim 1, in which R3 is —CH2—CH2—CH2—CH2—CH2—.

### Claim 8 (depends on 1)

The compound of claim 1, in which R2 is 2-chlorophenyl and R3 is —CH2—CH2—CH2—CH2—CH2—.

### Claim 9 (depends on 8)

The compound of claim 8, in which R4 is OH.

### Claim 10 (depends on 8)

The compound of claim 8, in which R4 is 2-aminophenyl.

### Claim 11 (depends on 8)

The compound of claim 8, in which R4 is 2-hydroxyphenyl.

### Claim 12 (depends on 1)

The compound of claim 1, selected from the group consisting of, UPHD-00157, UPHD-00165, UPHD-00166, UPHD-00186, UPHD-00187, or a pharmaceutically acceptable salt thereof.

### Claim 13

A compound having the formula:
in which
R is O, S, S(O), S(O)2, P(O)(CH3), or P(O)(OCH3),
R1 is methoxy or —NHR4 where R4 is OH, aminophenyl, hydroxyphenyl, hydroxypyridinyl, aminopyridinyl, alkyl hydroxypyridinyl, haloalkyl hydroxyphenyl,
R2 is phenyl, benzyl, 4-methoxybenzyl, phenylethyl, substituted phenyl,
where R5 is 3-hydroxyl; methylthio; methylsulfonyl, methylsulfinyl; acetyl; 2-acetato; 3-acetato; carbamoyl, methyl carbamoyl, and
R3 is —CH2—CH2—CH2—, —CH2—CH2—CH2—CH2—, or —CH2—CH2—CH2—CH2—CH2—, wherein
when R is S(O), S(O)2, R2 is benzyl, phenylethyl, or methylsulfonylphenyl; and
when R is S, either
(a) R1 is —NHR4 where R4 is hydroxypyridinyl, aminopyridinyl, alkyl hydroxypyridinyl, haloalkyl hydroxyphenyl;
(b) R1 is NHR4 where R4 is hydroxyphenyl or aminophenyl, and R2 is substituted phenyl,
where R5 is 4-acetato; or
(c) R2 is benzyl, phenylethyl, 4-methoxybenzyl, substituted phenyl,
where R5 is 3-hydroxyl; acetyl; 2-acetato; 3-acetato; carbamoyl, methyl carbamoyl,
or a pharmaceutically acceptable salt thereof.

### Claim 14 (depends on 13)

The compound of claim 13, in which R is O, P(O)(CH3), or P(O)(OCH3).

### Claim 15 (depends on 13)

The compound of claim 13, in which R3 is —CH2—CH2—CH2— or —CH2—CH2—CH2—CH2—CH2—.

### Claim 16 (depends on 13)

The compound of claim 13, in which R is O and R3 is —CH2—CH2—CH2—CH2—CH2—.

### Claim 17 (depends on 13)

The compound of claim 13, in which R is P(O)(CH3), or P(O)(OCH3) and R3 is —CH2—CH2—CH2— or —CH2—CH2—CH2—CH2—CH2—.

### Claim 18 (depends on 13)

The compound of claim 13, in which R is S(O) or S(O)2.

### Claim 19 (depends on 13)

The compound of claim 13, in which R1 is methoxy.

### Claim 20 (depends on 13)

The compound of claim 13, in which R is S(O) or S(O)2 and R1 is methoxy.

### Claim 21 (depends on 13)

The compound of claim 13, in which R2 is benzyl, 4-methoxybenzyl, phenylethyl.

### Claim 22 (depends on 13)

The compound of claim 13, in which R2 is substituted phenyl,
where R5 is 3-hydroxyl; methylthio; methylsulfonyl, methylsulfinyl; acetyl; 2-acetato; 3-acetato; carbamoyl, methyl carbamoyl.

### Claim 23 (depends on 13)

The compound of claim 13, in which when R is S and R1 is —NHR4 where R4 is hydroxypyridinyl, aminopyridinyl, alkyl hydroxypyridinyl, haloalkyl hydroxyphenyl.

### Claim 24 (depends on 13)

The compound of claim 13, in which when R is S and R2 is benzyl, phenylethyl, 4-methoxybenzyl, substituted phenyl,
where R5 is 3-hydroxyl; acetyl; 2-acetato; 3-acetato; carbamoyl, methyl carbamoyl.

### Claim 25 (depends on 13)

The compound of claim 13, selected from the group consisting of, UPHD-00146, UPHD-00149, UPHD-00150, UPHD-00151, UPHD-00152, UPHD-00153, UPHD-00154, UPHD-00155, UPHD-00156, UPHD-00158, UPHD-00161, UPHD-00162, UPHD-00168, UPHD-00170, UPHD-00171, UPHD-00174, UPHD-00175, UPHD-00176, UPHD-00178, UPHD-00179, UPHD-00180, UPHD-00181, UPHD-00185, UPHD-00188, UPHD-00189, UPHD-00190, UPHD-00191, UPHD-00192, UPHD-00193, UPHD-00194, UPHD-00195, UPHD-00196, UPHD-00197, UPHD-00198, UPHD-00199, UPHD-00201, UPHD-00202, UPHD-00203, UPH-D-00204, UPHD-00206, UPHD-00207, UPHD-00208, UPHD-00209, UPHD-00210, UPHD-00211, UPHD-00212, UPHD-00222, UPHD-00223, UPHD-00224, UPHD-00225, UPHD-00226, UPHD-00227, and UPHD-00228, or a pharmaceutically acceptable salt thereof.

### Claim 26 (depends on 1)

A composition comprising an amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof, effective to treat kidney injury or to improve kidney function in a patient and a pharmaceutically acceptable excipient.

### Claim 27 (depends on 1)

A method of treating kidney injury or improve kidney function in a patient comprising administering to a patient an amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof, effective to treat kidney injury or to improve kidney function in a patient.

### Claim 28 (depends on 27)

The method of claim 27, wherein the compound or pharmaceutically acceptable salt thereof is administered in an amount and in a dosage regimen effective to improve kidney function in a patient, to inhibit a histone deacylase in a cell, to expand renal progenitor cells and/or to stimulate kidney repair in cells in vitro, ex vivo or in vivo.

### Claim 29

(canceled)

### Claim 30 (depends on 13)

A composition comprising an amount of a compound of claim 13, or a pharmaceutically acceptable salt thereof, effective to treat kidney injury or to improve kidney function in a patient and a pharmaceutically acceptable excipient.

### Claim 31 (depends on 13)

A method of treating kidney injury or improve kidney function in a patient comprising administering to a patient an amount of a compound of claim 13, or a pharmaceutically acceptable salt thereof, effective to treat kidney injury or to improve kidney function in a patient.

### Claim 32 (depends on 31)

The method of claim 31, wherein the compound or pharmaceutically acceptable salt thereof is administered in an amount and in a dosage regimen effective to improve kidney function in a patient, to inhibit a histone deacylase in a cell, to expand renal progenitor cells and/or to stimulate kidney repair in cells in vitro, ex vivo or in vivo.
